Proteon Therapeutics, Inc. (NASDAQ:PRTO) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On December 13, 2016, the Company issued a press release
announcing the release of data from its first Phase 3 clinical
trial with investigational vonapanitase, PATENCY-1. The press
release is attached to this Current Report as Exhibit 99.1 hereto
and is incorporated herein by reference.
Further, officers and representatives of the Company will present
to various investors and stockholders beginning December 13, 2016
using the presentation materials furnished as Exhibit 99.2 hereto
and which are incorporated herein by reference.
The information in this report (including Exhibits 99.1 and 99.2)
shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liability of that section, and shall
not be incorporated by reference into any registration statement
or other document filed under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 |
Press Release, dated December 13, 2016, issued by Proteon Therapeutics, Inc. |
| 99.2 |
Presentation materials to be used by officers and other representatives of Proteon Therapeutics, Inc. |
About Proteon Therapeutics, Inc. (NASDAQ:PRTO)
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss. Proteon Therapeutics, Inc. (NASDAQ:PRTO) Recent Trading Information
Proteon Therapeutics, Inc. (NASDAQ:PRTO) closed its last trading session down -0.38 at 2.12 with 4,388,901 shares trading hands.